Row
H
HIMSAI Stock Diagnostic Report
Hims & Hers Health resumed at JP Morgan at neutral on GLP-1 compounding headwinds
JPMorgan resumed coverage on Hims & Hers Health with a neutral opinion due to headwinds related to GLP-1 copycat drugs.
View Source Article ↗
AI CATALYST SCORE50 / 100Score computed by Sentinel V12
REFERENCE PRICENot measuredReference entry price at analysis time
+ANALYSIS HISTORY
HIMS Analysis History (Last 30 Days)